Apr 28, 2024 Version 4

SARS-CoV-2 Mpro fluorescence dose response V.4

DOI
dx.doi.org/10.17504/protocols.io.81wgbye9nvpk/v4

Haim Barr[1,2], Noa Lahav[1,2]

[1]Weizmann Institute of Science; [2]ASAP Drug Discovery Consortium

Haim Barr: General acknowledgement: The Wohl Drug Discovery institute, The Nancy and Stephen Grand Israel National Center for Personalized Medicine.;

ASAP Discovery

Noa Lahav
Weizmann Institute

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN ACCESS

DOI: https://dx.doi.org/10.17504/protocols.io.81wgbye9nvpk/v4

Protocol Citation: Haim Barr, Noa Lahav 2024. SARS-CoV-2 Mpro fluorescence dose response. **protocols.io** **https://dx.doi.org/10.17504/protocols.io.81wgbye9nvpk/v4**Version created by **Mary-Ann Xavier**

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working
We use this protocol and it's working

Created: April 12, 2024

Last Modified: October 07, 2024

Protocol Integer ID: 98134

Keywords: SARS-CoV-2, Main Protease, dose response, Coronavirus, mpro fluorescence dose response, biochemical assay, direct enzyme activity measurement method, fluorescence intensity, part of the asap drug discovery consortium, asap drug discovery consortium, treatments for viral infectious disease, assay, viral infectious disease

Funders Acknowledgements:
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
Grant ID: U19AI171399

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Abstract

This is a **functional, biochemical assay** used to identify treatments for viral infectious disease that target SARS-COV-2 Main Protease (MPro).

Utilizing a **direct enzyme activity measurement method**, the experiment was performed in a 384-well plate reading the fluorescence intensity. This assay tested the mode of action of inhibition.

It was developed at the Weizmann Institute of Science, as a part of the ASAP Drug Discovery Consortium.

Experiment Assay Concentrations

	A	B	C
	Reagent	**Final Assay Concentration**	**Units**
	SARS Mpro	5	nM
	SARS Substrate	375	nM
	HEPES (pH 7.3)	20	mM
	NaCl	50	mM
	Glycerol	10	% by volume
	TWEEN 20	0.01	% by volume
	TCEP	1	mM

For more information, please check out the "Materials" Section

Guidelines

Plate Information:

Total Assay Volume: 20 µL
Compounds Top Assay Concentration: 100 µM
Dilution Factor: 2
Dose Response Points: 12
Number of Replicates: 2
Backfill with DMSO: Yes

Materials

Assay Buffer Reagents (Concentration listed are Stock Solution Concentrations)

1. [M] 40 millimolar (mM) HEPES 1M Solution pH 7.3 **Fisher Scientific Catalog #**AAJ16924K2 (or similar)
2. [M] 100 millimolar (mM) Sodium chloride **Merck MilliporeSigma (Sigma-Aldrich) Catalog #**S9888-25G (or similar)
3. [M] 50 % volume Glycerol **Merck MilliporeSigma (Sigma-Aldrich) Catalog #**G5516 (or similar)
4. [M] 10 % volume TWEEN® 20 **Merck MilliporeSigma (Sigma-Aldrich) Catalog #**P9416 (or similar)
5. [M] 1000 millimolar (mM) Tris(2-carboxyethyl)phosphine hydrochloride **Merck MilliporeSigma (Sigma-Aldrich) Catalog #**75259 (TCEP) (or similar)

***Note:** all components are added fresh to the assay buffer before each experiment

---

Additional Reagents:

[M] 710 micromolar (µM) **SARS MPro Enzyme**

- The Enzyme original stock was originally [M] 750 micromolar (µM) and was diluted to create aliquots of [M] 20000 nanomolar (nM) using a **storage buffer** (50 mM Tris pH 7.5, 1 mM DTT, 50 mM NaCl, 1 mM EDTA, 50% Glycerol).
- Before an experiment, the 20000 nM aliquots were **diluted with Assay Buffer** to create a [M] 10 nanomolar (nM) solution to be loaded into the Combi.

[M] 20000 micromolar (µM) **SARS MPro Substrate**

- SARS MPro Substrate Stock ([5-FAM]-AVLQSGFR-[Lys(Dabcyl)-K-amide) was purchased and dissolved in **DMSO** and yielded a concentration of [M] 20000 micromolar (µM)
- Before an experiment, the SARS MPro Substrate Stock had an *intermediate dilution step* with **DMSO** to yield a [M] 100 micromolar (µM) SARS MPro Substrate Solution. Then, before adding the SARS MPro Substrate to the Combi, it was diluted again with **Assay Buffer** to yield a concentration of [M] 750 nanomolar (nM). The final concentration of **SARS MPro Substrate** for the assay was [M] 375 nanomolar (nM)

Troubleshooting

Safety warnings

Please be sure to wear proper Personal Protective Equipment (PPE) while performing this experiment.

Before start

Note: Inhibitor compounds stock concentration is **20 mM**. Compounds are pre-dispensed into 384 plates and stored at -200˚C until use.

Prepare 384 Well Plate

1 **PRIME** Multi-Drop Combi Tube Dispensing Cassette with **Assay Buffer** by selecting the **PRIME** button on the Combi Dispenser until the tubes are filled completely.

1.1 **DISPENSE** 10 µL Assay Buffer to Columns **1** and **23** of assay plate

- **Note:** These will represent the ***inhibitor control columns*** (Contain: Substrate, Assay Buffer, DMSO; **no experimental compounds**)

1.2 **EMPTY** Multi-Drop Combi Tube Dispensing Cassette (by selecting the **EMPTY** button on the Combi Dispenser until the tubes of the cassette are emptied). Discard the Assay Buffer discharged from the cassette.

Prepare Reagents

2 **PRIME** Multi-Drop Combi Tube Dispensing Cassette with [M] 10 nanomolar (nM) SARS MPro by selecting the **PRIME** button on the Combi Dispenser until the tubes were filled completely.

- **Note:** Be sure to cycle dispensing several times on a a clean plate lid (This confirms there are no bubbles in the Dispensing Cassette).

2.1 **DISPENSE** 10 µL [M] 10 nanomolar (nM) SARS MPro to Columns **2** through **22** and also Column **24.**

Note:

- [M] 10 nanomolar (nM) SARS Mpro is two times the final concentration for the assay. It is diluted to be a final concentration of [M] 5 nanomolar (nM) SARS MPro .
- Column 2 and Column 24 are ***neutral control columns*** (Contain: Enzyme, Substrate, DMSO; **no experimental compounds**)

2.2 **EMPTY** Multi-Drop Combi Tube Dispensing Cassette (by selecting the **EMPTY** button on the Combi Dispenser until the tubes of the cassette are emptied). Discard the [M] 10 nanomolar (nM) SARS MPro discharged from the cassette.

3 **CENTRIFUGE** 15000 rpm, Room temperature, 00:01:00 plate to remove bubbles 1m

4 **INCUBATE** plate for 00:15:00 at Room temperature 15m

5 **PRIME** Multi-Drop Combi Tube Dispensing Cassette with **Assay Buffer** by selecting the **PRIME** button on the Combi Dispenser until the tubes are filled completely. Then, **EMPTY** the Multi-Drop Combi Tube Dispensing Cassette (by selecting the **EMPTY** button on the Combi Dispenser until the tubes of the cassette are emptied). **Discard the Assay Buffer discharged from the cassette.**

6 **PRIME** Multi-Drop Combi Tube Dispensing Cassette with [M] 750 nanomolar (nM) SARS Substrate by selecting the **PRIME** button on the Combi Dispenser until the tubes were filled completely.

- **Note:** Be sure to cycle dispensing several times on a a clean plate lid (This confirms there are no bubbles in the Dispensing Cassette).

6.1 **DISPENSE** 10 µL [M] 750 nanomolar (nM) SARS Substrate into Columns **1 through 24** (the full plate)

Note:

- [M] 750 nanomolar (nM) SARS Substrate is two times the final concentration for the assay. It is diluted to be a final concentration of [M] 375 nanomolar (nM) SARS Substrate

7 **CENTRIFUGE** plate at 15000 rpm, Room temperature, 00:01:00 in plate centrifuge to remove bubbles 1m

8 **INCUBATE** plate at Room temperature for 00:30:00 30m

⚠ **Make sure the plate is protected from light!**

Recommended: Clean/Empty the Multi-Drop Combi Reagent Dispenser and Dispensing Cassette during this incubation step

Read Plate Fluorescence

9 **READ** and **RECORD** the plate Relative fluorescence units (RFU) via the **"SARS Endpoint protocol"** on the **PHERAstar FS Control Software**.

Expected result

Gain 300 should yield ~10,000 RFU in full reaction and ~6,000 RFU in Buffer Control